Added to YB: 2026-09-14
Pitch date: 2026-09-10
ACRV [neutral]
Acrivon Therapeutics, Inc.
Author Info
No bio for this author
Company Info
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform.
Market Cap
$85.3M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
0.03
P/E
-1.06
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Biotech Conference Coverage Day 2 Section 3 - $ACRV
ACRV (quick overview): Acrivon is a high-risk validation play on its AP3 AI-driven phosphoproteomics platform, with a decisive Q4 interim readout for ACR-368 in serous endometrial cancer. Earlier data showed roughly 50% response across monotherapy and low-dose gemcitabine arms; management believes about 30% with meaningful durability could be clinically important. The case depends on that signal surviving prospective enrollment, potentially supporting a simpler monotherapy registration path.
Read full article (1 min)